{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:23:47Z","timestamp":1761920627640,"version":"3.37.3"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0222288","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T18:32:46Z","timestamp":1568313166000},"page":"e0222288","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis"],"prefix":"10.1371","volume":"14","author":[{"given":"Jianzhen","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-9088","authenticated-orcid":true,"given":"Yanmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"issue":"9648","key":"pone.0222288.ref001","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple Sclerosis","volume":"372","author":"A Compston","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"pone.0222288.ref002","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for Multiple Sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"CH Polman","year":"2011","journal-title":"Ann Neurol"},{"volume-title":"Multiple Sclerosis Information Sourcebook","year":"2005","author":"National Multiple Sclerosis Society","key":"pone.0222288.ref003"},{"issue":"4","key":"pone.0222288.ref004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1586\/erp.10.34","article-title":"Impact of mobility impairment on the burden of caregiving in individuals with Multiple Sclerosis","volume":"10","author":"J Dunn","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"pone.0222288.ref005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s13167-011-0136-4","article-title":"Exercise in Multiple Sclerosis\u2013an integral component of disease management","volume":"3","author":"A Doring","year":"2011","journal-title":"The EPMA Journal"},{"key":"pone.0222288.ref006","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1185\/03007995.2013.787979","article-title":"Consensus guidelines for the diagnosis and treatment of Multiple Sclerosis","volume":"29","author":"B Yamout","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"pone.0222288.ref007","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/2040622313492810","article-title":"Teriflunomide in relapsing Multiple Sclerosis: therapeutic utility","volume":"4","author":"MS Freedman","year":"2013","journal-title":"Ther. Adv Chron Dis"},{"issue":"2","key":"pone.0222288.ref008","first-page":"129","article-title":"\u8fbe\u65b9\u5421\u5576\u6539\u5584\u591a\u53d1\u6027\u786c\u5316\u76f8\u5173\u7684\u884c\u8d70\u969c\u788d","volume":"2","author":"\u4ead\u4ead \u6768","year":"2012","journal-title":"\u4e2d\u534e\u8111\u79d1\u75be\u75c5\u4e0e\u5eb7\u590d\u6742\u5fd7"},{"issue":"2","key":"pone.0222288.ref009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1756285613512712","article-title":"4-Aminopyridine for symptomatic treatment of Multiple Sclerosis: a systematic review","volume":"7","author":"HB Jensen","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"pone.0222288.ref010","doi-asserted-by":"crossref","first-page":"34749","DOI":"10.1038\/srep34749","article-title":"4-Aminopyridine sequesters intracellular Ca2+ which triggers exocytosis in excitable and non-excitable cells","volume":"6","author":"LA Kasatkina","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0222288.ref011","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/17425255.2015.993315","article-title":"Pharmacology and clinical efficacy of DAP for treating Multiple Sclerosis","volume":"11","author":"A Lugaresi","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"pone.0222288.ref012","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0306-4522(96)00477-0","article-title":"Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord","volume":"77","author":"R Shi","year":"1997","journal-title":"Neuroscience"},{"issue":"52","key":"pone.0222288.ref013","doi-asserted-by":"crossref","first-page":"36453","DOI":"10.1074\/jbc.M109.075523","article-title":"Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit","volume":"284","author":"ZZ Wu","year":"2009","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0222288.ref014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40263-018-0586-5","article-title":"Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine","volume":"33","author":"J Hobart","year":"2019","journal-title":"Cns Drugs"},{"key":"pone.0222288.ref015","doi-asserted-by":"crossref","unstructured":"Satchidanand N, Drake A, Smerbeck A, Hojnacki D, Kolb C, Patrick B, et al. DAP benefits ambulation but not cognition in Multiple Sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 2018: 1352458518815795.","DOI":"10.1177\/1352458518815795"},{"issue":"1","key":"pone.0222288.ref016","first-page":"1","article-title":"Prolonged-Release Fampridine as Adjunct Therapy to Active Motor Training in Mobility Disability Patients: A Pilot, Double-Blind, Randomized, Placebo-Controlled Study","volume":"4","author":"F Jacques","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"pone.0222288.ref017","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1352458515581436","article-title":"Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial","volume":"22","author":"R Hupperts","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"key":"pone.0222288.ref018","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.msard.2016.07.019","article-title":"Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of Mobility Disability patients. A randomized, double blind, placebo controlled study","volume":"10","author":"HB Jensen","year":"2016","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"pone.0222288.ref019","first-page":"138","article-title":"Evaluation of DAP Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial","volume":"17","author":"R Yapundich","year":"2015","journal-title":"International journal of Mobility Disability care"},{"key":"pone.0222288.ref020","unstructured":"DAP for Imbalance in Multiple Sclerosis. URL: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01444300."},{"key":"pone.0222288.ref021","unstructured":"Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis. URL: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00053417."},{"issue":"4","key":"pone.0222288.ref022","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A Phase 3 Trial of Extended Release Oral DAP in Multiple Sclerosis","volume":"68","author":"AD Goodman","year":"2010","journal-title":"Annals of Neurology"},{"issue":"9665","key":"pone.0222288.ref023","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in Multiple Sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"AD Goodman","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"pone.0222288.ref024","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/1352458517690823","article-title":"Validity of the timed 25-foot walk as an ambulatory performance outcome measure for Multiple Sclerosis","volume":"23","author":"R. W. Motl","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"key":"pone.0222288.ref025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/WNL.0b013e3182872855","article-title":"Disability in Multiple Sclerosis: a reference for patients and clinicians","volume":"80","author":"I Kister","year":"2013","journal-title":"Neurology"},{"key":"pone.0222288.ref026","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12883-017-0844-z","article-title":"Healthcare resource use and costs of Multiple Sclerosis patients in Germany before and during fampridine treatment","volume":"17","author":"T Ziemssen","year":"2017","journal-title":"BMC Neurol"},{"issue":"5","key":"pone.0222288.ref027","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.clinthera.2012.03.007","article-title":"The safety profile of DAP extended release in Multiple Sclerosis clinical trials","volume":"34","author":"DR Cornblath","year":"2012","journal-title":"Clin Ther"},{"issue":"2","key":"pone.0222288.ref028","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinthera.2009.02.004","article-title":"Pharmacokinetics of 14 Cradioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers","volume":"31","author":"AR Blight","year":"2009","journal-title":"Clin Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0222288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T15:30:49Z","timestamp":1589038249000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0222288"}},"subtitle":[],"editor":[{"given":"Wisit","family":"Cheungpasitporn","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0222288","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}